Why Becton Dickinson Is Poised to Outperform

Brian Pacampara, Pacampara, The Motley Fool
Updated

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical-device maker Becton, Dickinson and Company has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Becton Dickinson and see what CAPS investors are saying about the stock right now.

Becton Dickinsonfacts

Headquarters (founded)

Franklin Lakes, N.J. (1897)

Market Cap

$17.4 billion

Industry

Health care equipment

Trailing-12-Month Revenue

$7.8 billion

Management

Chairman/CEO Vincent Forlenza
Acting CFO Suketu Upadhyay

Return on Equity (average, past 3 years)

23.9%

Cash/Debt

$2.5 billion / $4.2 billion

Dividend Yield

2.2%

Competitors

Abbott Labs
Baxter International
Covidien


Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 98% of the 1,168 members who have rated Becton Dickinson believe the stock will outperform the S&P 500 going forward.

Earlier this month, one of those Fools, bloomr, succinctly summed up the Becton Dickinson bull case for our community: "The population is getting older. ... Diabetes is an epidemic. Everybody hates needles, but [Becton Dickinson] has been a leader for years with a consistently solid dividend yield to boot."

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong five-star rating, Becton Dickinson may not be your top choice.

If that's the case, we've compiled a special free report for investors called "The 3 Dow Stocks Dividend Investors Need," which uncovers a few other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The article Why Becton Dickinson Is Poised to Outperform originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Becton Dickinson and Covidien. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement